Amphastar Pharmaceuticals Inc   (AMPH)
Other Ticker:  
Price: $57.9200 $1.60 2.841%
Day's High: $58.58 Week Perf: 2.35 %
Day's Low: $ 56.12 30 Day Perf: 27.46 %
Volume (M): 457 52 Wk High: $ 67.66
Volume (M$): $ 26,469 52 Wk Avg: $43.77
Open: $56.89 52 Wk Low: $27.58

 Market Capitalization (Millions $) 3,123
 Shares Outstanding (Millions) 54
 Employees 2,146
 Revenues (TTM) (Millions $) 601
 Net Income (TTM) (Millions $) 135
 Cash Flow (TTM) (Millions $) 114
 Capital Exp. (TTM) (Millions $) 35

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc is a publicly traded American pharmaceutical company founded in 1996 by Drs. Jack and Rex Zhang. The company is headquartered in Rancho Cucamonga, California and has a market capitalization of over $1 billion. Amphastar specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products.

The company has more than 20 injectable products in its portfolio, which includes anesthesia, analgesics, anti-infectives, cardiovascular, and central nervous system agents. Amphastar's most significant revenue generating product is enoxaparin sodium injection, a generic version of Sanofi's anticoagulant Lovenox. This product accounts for more than 50% of the company's total revenue.

Additionally, Amphastar has branded products, such as Primatene Mist, an over-the-counter inhaler used for the treatment of asthma symptoms. The company also has a pipeline of innovative products, including products in clinical trials for diabetes, hypoglycemia, and severe allergies.

The company has three manufacturing facilities located in California, which are equipped with the latest manufacturing technology and conform to the highest regulatory standards of the FDA and the European Medicines Agency (EMA).

In addition to its manufacturing capabilities, Amphastar has a robust research and development team that is responsible for developing new products and improving existing products. The company invests heavily in research and development, spending around 20% of its revenue on these activities.

Amphastar has a global presence and has distribution partnerships in many countries, including the United States, Europe, and Asia. The company has a diverse customer base that includes hospitals, wholesalers, and distributors.

Amphastar is committed to corporate social responsibility and strives to reduce its impact on the environment. The company has implemented sustainability programs that focus on energy efficiency, water conservation, and waste management.

In summary, Amphastar Pharmaceuticals is a leading pharmaceutical company that specializes in the development, manufacturing, and marketing of generic and proprietary injectable and inhalation products. With a wide range of products, an innovative pipeline, and a strong commitment to sustainability, Amphastar is poised for continued growth and success in the pharmaceutical industry.

   Company Address: 11570 6th Street Rancho Cucamonga 91730 CA
   Company Phone Number: 980-9484   Stock Exchange / Ticker: NASDAQ AMPH
   AMPH is expected to report next financial results on February 29, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

For the fiscal third quarter of 2023 ONTX lost money of $-0.23 per share compare to $-0.26 a year ago and surged deficit from $-0.20 per share from the previous quarter. The revenue remained unaffected by 0 % to $0.06 million from $0.06 million in the same quarter a year ago and sequentially Revenue remained constant from $0.06 million.


Amphastar Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com